FR2785188B1 - Formulations stables d'apomorphine en solution - Google Patents

Formulations stables d'apomorphine en solution

Info

Publication number
FR2785188B1
FR2785188B1 FR9913521A FR9913521A FR2785188B1 FR 2785188 B1 FR2785188 B1 FR 2785188B1 FR 9913521 A FR9913521 A FR 9913521A FR 9913521 A FR9913521 A FR 9913521A FR 2785188 B1 FR2785188 B1 FR 2785188B1
Authority
FR
France
Prior art keywords
apomorphin
solution
stable formulations
formulations
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9913521A
Other languages
English (en)
Other versions
FR2785188A1 (fr
Inventor
Eva Bernini
Gaetano Brambilla
Paolo Chiesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of FR2785188A1 publication Critical patent/FR2785188A1/fr
Application granted granted Critical
Publication of FR2785188B1 publication Critical patent/FR2785188B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR9913521A 1998-10-30 1999-10-28 Formulations stables d'apomorphine en solution Expired - Fee Related FR2785188B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002331A IT1303684B1 (it) 1998-10-30 1998-10-30 Formulazioni di apomorfina in soluzione stabili nel tempo.

Publications (2)

Publication Number Publication Date
FR2785188A1 FR2785188A1 (fr) 2000-05-05
FR2785188B1 true FR2785188B1 (fr) 2004-10-29

Family

ID=11380970

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9913521A Expired - Fee Related FR2785188B1 (fr) 1998-10-30 1999-10-28 Formulations stables d'apomorphine en solution

Country Status (6)

Country Link
BR (1) BR9905305A (fr)
ES (1) ES2156763B1 (fr)
FR (1) FR2785188B1 (fr)
GB (1) GB2343376B (fr)
GR (1) GR990100373A (fr)
IT (1) IT1303684B1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002947A3 (cs) * 1999-09-29 2002-08-14 The Procter & Gamble Company Kapalný prostředek, nejlépe orální prostředek se zlepąenou stabilitou a způsob přípravy
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TR201903492T4 (tr) 2012-06-05 2019-04-22 Neuroderm Ltd Apomorfin ve organik asitler içeren bileşimler ve bunların kullanım alanları.
WO2015157212A1 (fr) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Composition stable d'apomorphine et ses utilisations

Also Published As

Publication number Publication date
BR9905305A (pt) 2001-03-20
ITMI982331A1 (it) 2000-04-30
FR2785188A1 (fr) 2000-05-05
GB2343376B (en) 2003-12-31
GB2343376A (en) 2000-05-10
IT1303684B1 (it) 2001-02-23
GB9925602D0 (en) 1999-12-29
ES2156763B1 (es) 2002-03-01
GR990100373A (el) 2000-06-30
ES2156763A1 (es) 2001-07-01

Similar Documents

Publication Publication Date Title
IS2325B (is) Örgerðar samsetningar epleróns
ID18666A (id) Penggunaan komposisi komposisi yang terdiri dari senyawa senyawa stabil yang efektif secara biologi
NO20026001D0 (no) 3'-promedikamenter av 2'-deoksy-<Beta>-L-nukleosider
ID29021A (id) Komposisi galantamina pelepasan terkontrol
ATE279114T1 (de) Dermal applizierbare wasserhaltige formulierungen von parasitiziden
FR2779192B1 (fr) Accouplement d'arbres
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
ID18832A (id) Komposisi insektisida
ID25765A (id) Komposisi pembersih kulit
FR2785188B1 (fr) Formulations stables d'apomorphine en solution
MA24801A1 (fr) Compositions de blanchiment stables
DE19781549T1 (de) Desinfektionszusammensetzung "Weltolen"
IT244003Y1 (it) Tenuta d'albero
LU90560B1 (fr) B-timent d'-levage d'animaux - ventelles
ID23774A (id) Komposisi insektisida
ID23032A (id) Komposisi insektisida
ITMI20000629A0 (it) Composti con attivita' anti-hiv
ID23006A (id) 13-dihidro-3' aziridino antrasiklina
KR980000150U (ko) 낚시찌의 찌톱
UA2100S (uk) Комплект етикеток "хортиця"
UA2400S (uk) Набір етикеток "ужгород"
UA2269S (uk) Комплект етикеток "миротворча"
UA2189S (uk) Комплект етикеток "стольник"
UA2918S (uk) Комплект етикеток "славутич"
UA2501S (uk) Набір етикеток "кутузов"

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20120629